[Elsevier] Aztreonam每avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial |
|
This post will be closed automatically in 2026-07-19 08:10
Reward20points
|
post
reply
points
210
10
Advancements in green hydrogen production: A comprehensive review of prospects, challenges, and innovations in electrolyzer technologies
10
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
10
AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology
10
ABS1255-PAREINSIGHTS FROM THE ADULT DERMATOMYOSITIS EL-PFDD: CAPTURING PATIENT PERSPECTIVES TO IMPROVE GLOBAL MYOSITIS CARE
30
[Other]Diagnosis of thyroid nodules
